* Ribi ImmunoChem Research Inc., of Hamilton, Mont., amended theterms of warrants issued in 1992. The exercise price of $11.55 pershare with an April 1 deadline was changed to $6 per share with anexpiration date of April 1, 1997.

* Gensia Inc., of San Diego, received a product license to market theGenESA system in Ireland. It already was approved in the U.K. andin Sweden.

* U.S. Bioscience Inc., of West Conshohocken, Pa., was granted aproduct license in France to market Ethyol, a selective cytoprotectiveagent. France is the fifth European country to grant approval.

* Diatech Inc., of Londonderry, N.H., received a grant from the U.S.Energy Department to support trials of Tin-117m-DTPA, aradiopharmaceutical therapeutic for the palliation of painful bonemetastases in cancer patients.

* Boston Scientific Corp., of Natick, Mass., renewed its researchagreement with St. Elizabeth's Hospital, of Brighton, Mass., in thefield of cardiovascular gene therapy.

(c) 1997 American Health Consultants. All rights reserved.

No Comments